However, when these same pVHL-restored RCC cells are engineered to express a stable Hif2α variant lacking its prolyl hydroxylation/pVHL binding sites, they regain their ability to form tumors in vivo[76]. This evidence concerns the gene VHL and renal cell carcinoma.